Identification of Novel Cyclooxygenase-1 Selective Inhibitors of Thiadiazole-Based Scaffold as Potent Anti-Inflammatory Agents with Safety Gastric and Cytotoxic Profile
Molecules · 2023
DOI: 10.3390/molecules28083416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Michelyne Haroun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia. Hauptthemen laut MEDLINE: Thiadiazoles, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia.
Abstract (Originalsprache)
Major obstacles faced by the use of nonsteroidal anti-inflammatory drugs (NSAID) are their gastrointestinal toxicity induced by non-selective inhibition of both cyclooxygenases (COX) 1 and 2 and their cardiotoxicity associated with a certain class of COX-2 selective inhibitors. Recent studies have demonstrated that selective COX-1 and COX-2 inhibition generates compounds with no gastric damage. The aim of the current study is to develop novel anti-inflammatory agents with a better gastric profile. In our previous paper, we investigated the anti-inflammatory activity of 4-methylthiazole-based thiazolidinones. Thus, based on these observations, herein we report the evaluation of anti-inflammatory activity, drug action, ulcerogenicity and cytotoxicity of a series of 5-adamantylthiadiazole-based thiazolidinone derivatives. The in vivo anti-inflammatory activity revealed that the compounds possessed moderate to excellent anti-inflammatory activity. Four compounds 3, 4, 10 and 11 showed highest potency (62.0, 66.7, 55.8 and 60.0%, respectively), which was higher than the control drug indomethacin (47.0%). To determine their possible mode of action, the enzymatic assay was conducted against COX-1, COX-2 and LOX. The biological results demonstrated that these compounds are effective COX-1 inhibitors. Thus, the IC50 values of the three most active compounds 3, 4 and 14 as COX-1 inhibitors were 1.08, 1.12 and 9.62 μΜ, respectively, compared to ibuprofen (12.7 μΜ) and naproxen (40.10 μΜ) used as control drugs. Moreover, the ulcerogenic effect of the best compounds 3, 4 and 14 were evaluated and revealed that no gastric damage was observed. Furthermore, compounds were found to be nontoxic. A molecular modeling study provided molecular insight to rationalize the COX selectivity. In summary, we discovered a novel class of selective COX-1 inhibitors that could be effectively used as potential anti-inflammatory agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
- School of Pharmacy, Aristotle, University of Thessaloniki, 54124 Thessaloniki, Greece.
- Division of Infectious Diseases, Weill Cornell Medicine, New York, NY 10065, USA.
- Department of Biotechnology and Food Technology, Faculty of Applied Sciences, Durban University of Technology, Durban 4001, South Africa.
- Department of Chemistry, College of Science, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
- Basic & Applied Scientific Research Center, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
ORCID-Profile: Anthi Petrou, Panagiotis Zagaliotis, Katharigatta N Venugopala, Promise M Emeka, Nancy S Younis, Dalia Ahmed Elmaghraby, Mervt M Almostafa, Ioannis S Vizirianakis, Athina Geronikaki
Förderung
- Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia
Zitieren
APA
Haroun, M., Fesatidou, M., Petrou, A., Tratrat, C., Zagaliotis, P., Gavalas, A., Venugopala, K. N., Kochkar, H., Emeka, P. M., Younis, N. S., Elmaghraby, D. A., Almostafa, M. M., Chohan, M. S., Vizirianakis, I. S., Papadimitriou-Tsantarliotou, A., & Geronikaki, A. (2023). Identification of Novel Cyclooxygenase-1 Selective Inhibitors of Thiadiazole-Based Scaffold as Potent Anti-Inflammatory Agents with Safety Gastric and Cytotoxic Profile. Molecules. https://doi.org/10.3390/molecules28083416
Vancouver
Haroun M, Fesatidou M, Petrou A, Tratrat C, Zagaliotis P, Gavalas A, et al. Identification of Novel Cyclooxygenase-1 Selective Inhibitors of Thiadiazole-Based Scaffold as Potent Anti-Inflammatory Agents with Safety Gastric and Cytotoxic Profile. Molecules. 2023. doi:10.3390/molecules28083416
BibTeX
@article{Haroun2023,
author = {Haroun, Michelyne and Fesatidou, Maria and Petrou, Anthi and Tratrat, Christophe and Zagaliotis, Panagiotis and Gavalas, Antonis and Venugopala, Katharigatta N and Kochkar, Hafedh and Emeka, Promise M and Younis, Nancy S and Elmaghraby, Dalia Ahmed and Almostafa, Mervt M and Chohan, Muhammad Shahzad and Vizirianakis, Ioannis S and Papadimitriou-Tsantarliotou, Aliki and Geronikaki, Athina},
title = {Identification of Novel Cyclooxygenase-1 Selective Inhibitors of Thiadiazole-Based Scaffold as Potent Anti-Inflammatory Agents with Safety Gastric and Cytotoxic Profile},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28083416}
}
EUVIMED